ClinicalTrials.gg
CompletedNCT00065130Updated Dec 22, 2016

Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes

A Phase 3 interventional study of human insulin and insulin NPH in Diabetes and Gestational Diabetes, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-22.

Primary conditionDiabetes, GestationalRegistry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes, Gestational
Why
  1. The study's listed conditions name Diabetes, Gestational, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 251 studies in Diabetes, Gestational with a site in United States — 52 open to participants now, 65 under way, 2 of them phase 3. Diabetes, Gestational · United States.

Enrollment
151st of 194
27 · median 80
Started
2000
the only one that year
Phase 3
7 of 251
1 open now
Registered
1st of 251
by date

Among the 251 studies in Diabetes, Gestational with a site in United States, this one is the 151st largest by enrollment of the 194 interventional ones that give a count, is the only one that started in 2000, is one of 7 in phase 3, and was the 1st registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 198 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

52 of the 251 studies in Diabetes, Gestational with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 134 Diabetes, Gestational studies recruiting now, 62 (46%) set no upper age limit and 70 (52%) stop at 75 or younger; 13 take children under 18; 61 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Diabetes, Gestational with a site in United States, or all of them as a file.
02

Study summary

This trial is conducted in the United States of America (USA). The purpose of this study is to test whether NovoLog (insulin aspart) is a safe and at least as effective alternative to regular human insulin for the control of blood glucose after meals in women who develop diabetes during pregnancy.

03

Conditions studied

  • Diabetes
  • Gestational Diabetes

Browse trials for

04

In context

Diabetes, Gestational Reclassified

878 studies on the registry are indexed under Diabetes, Gestational; 198 are open to participants now.

This study's enrollment of 27 is below the median of 110 across 564 interventional studies indexed under Diabetes, Gestational.

Browse Diabetes, Gestational studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes, Gestational, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Subjects older than 35 years old will be considered
  • Gestational diabetes mellitus
06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Interventions

07

What researchers measure

Primary outcomes

  1. Postprandial glycemic control

Secondary outcomes

  1. HbA1c (glycosylated haemoglobin A1c)

  2. Postprandial endogenous insulin secretory response

  3. Hypoglycemic episodes

  4. Adverse events

08

Study locations

1 site
  • Novo Nordisk Investigational Site
    Santa Barbara, California 93105, United States
09

References and documents

Publications

  • Pettitt DJ, Ospina P, Kolaczynski JW, Jovanovic L. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care. 2003 Jan;26(1):183-6. doi: 10.2337/diacare.26.1.183. PubMed 12502678 ↗
  • Pettitt DJ, Ospina P, Howard C, Zisser H, Jovanovic L. Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus. Diabet Med. 2007 Oct;24(10):1129-35. doi: 10.1111/j.1464-5491.2007.02247.x. PubMed 17888133 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2000, a primary completion of Dec 2003 and a completion of Dec 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2003
First posted
Jul 18, 2003
Start
Apr 2000
Primary completionActual
Dec 2003
CompletionActual
Dec 2003
Last update
Dec 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00065130
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 18, 2003
Start date
Apr 2000
Primary completion
Dec 2003
Completion
Dec 2003
Last update
Dec 22, 2016

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin, Regular, Human · Insulin Aspart

Start the discussion